Previous 10 | Next 10 |
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program PR Newswire MONMOUTH JUNCTION, N.J. , April 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of li...
CytoSorbents Corporation (NASDAQ:CTSO) traded today at a new 52-week high of $15.00. So far today approximately 27.3 million shares have been exchanged, as compared to an average 30-day volume of 162,000 shares. CytoSorbents Corp is a critical care immunotherapy leader commercializing it...
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors PR Newswire MONMOUTH JUNCTION , N.J. , April 5, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive c...
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM) PR Newswire MONMOUTH JUNCTION, N.J. , March 17, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in...
Gainers: Sunshine Biopharma (NASDAQ:SBFM) +159%. Cano Health (NYSE:CANO) +34%. Celyad Oncology (NASDAQ:CYAD) +24%. Mainz Biomed (NASDAQ:MYNZ) +21%. Bright Health Group (NYSE:BHG) +17%. Losers: Ontrak (NASDAQ:OTRK) -20%. Invacare (NYSE:IVC) -19%. Na...
Cytosorbents Corporation (CTSO) Q4 2021 Earnings Conference Call March 8, 2022 16:30 ET Company Participants Terri Anne Powers - Vice President, Investor Relations and Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathl...
Cytosorbents press release (NASDAQ:CTSO): Q4 GAAP EPS of -$0.21. Revenue of $10.8M (-10.0% Y/Y). Outlook: The company expects continued and progressive improvement in its underlying core non-COVID-19 business in 2022, with growth of 20% or more in 2022 core product sales, compared to $33...
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook 2021 total revenue was $43.2 million, including product sales of $40.1 million. Core non-COVID-19 product sales increased approximately 13% Y-Y to $33.8 million. 2022 marks the 10th anni...
ABM, ADES, ANIK, AQST, ATER, AXDX, BEST, BKEP, BMBL, CASY, CDMO, CIVI, CRCT, CTSO, DADA, EVOK, FIGS, FLL, FLNT, FTEK, GLRE, GWRE, HDSN, MDB, MNTS, OTRK, PRSO, SFIX, SNCR, SND, SUMO, WTI, YEXT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable...
Cytosorbents (NASDAQ:CTSO) is scheduled to announce Q4 earnings results on Tuesday, March 8th, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $10.8M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue estim...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...